Showing papers by "Dale G. Renlund published in 2002"
TL;DR: A patient with Becker muscular dystrophy-related cardiomyopathy is described, in whom improvement of cardiac status is noted with carefully titrated medical therapy, which suggests a trial of medical therapy may be beneficial when patients with Becker muscle-based dystrophinopathy are evaluated for transplant.
Abstract: Patients with Becker muscular dystrophy-related cardiomyopathy typically survive into their 30s, when they succumb to complications of cardiomyopathy or receive heart transplants. The cardiomyopathy is related to an abnormality in the protein dystrophin; no successful medical responses have been reported to date. We describe a patient with Becker muscular dystrophy-related cardiomyopathy in whom we noted improvement of cardiac status with carefully titrated medical therapy. Successful therapy suggests a trial of medical therapy may be beneficial when patients with Becker muscular dystrophy-related cardiomyopathy are evaluated for transplant.
17 citations
TL;DR: To test the hypothesis that BB therapy can be safely administered to, and improves cardiac function in elderly patients with HF, patients who were randomized to receive the BB bucindolol or placebo in the Beta-Blocker Evaluation of Survival Trial (BEST) were analyzed.
Abstract: E evidence and clinical trials have shown the beneficial effects of -adrenergic blockers (BBs) in patients with heart failure (HF). A large database supports the contention that BB therapy improves survival, reduces the rate of hospitalization, delays the progression of HF, and improves cardiac function. However, there is little information regarding how elderly patients with HF tolerate and respond to BBs. To test the hypothesis that BB therapy can be safely administered to, and improves cardiac function in elderly patients with HF, we analyzed, according to age, patients who were randomized to receive the BB bucindolol or placebo in the Beta-Blocker Evaluation of Survival Trial (BEST).
17 citations
TL;DR: Strategies to monitor patients with acute vascular rejection include monitoring of serum antibody titers coupled with frozen section immunohistochemistry and treatment strategies include plasmapheresis and immunosuppressive regimens containing cyclophosphamide or mycophenolate mofetil.
Abstract: Acute vascular (microvascular) rejection is a term that has been applied to the morphologic appearance of rejection responses involving the allograft vasculature. Recent studies have highlighted the diverse mechanisms that can be responsible for this morphologic appearance. Features of microvascular injury caused by reperfusion injury are related to complement mediated effects that are operative in both reperfusion as well as humorally mediated allograft rejection. Recent work has documented the importance of antibody and complement in mediating antigen-dependent microvascular damage and its relation to cardiac allograft vasculopathy. Strategies to monitor patients with acute vascular rejection include monitoring of serum antibody titers coupled with frozen section immunohistochemistry. Treatment strategies include plasmapheresis and immunosuppressive regimens containing cyclophosphamide or mycophenolate mofetil.
10 citations
7 citations
2 citations